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INTRODUCTION 
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INTRODUCTION 
 
For decades the role of LDL cholesterol in predicting the risk of 
coronary and cerebrovascular events has been well established.  It is now 
clear that LDL is not the only atherogenic particle. But other particles that 
contain apoprotein B such as VLDL, VLDL remnants, IDL, and 
Chylomicron remnants are important. This is reflected in the non HDL 
cholesterol value which is a simple measure. It does not require fasting 
specimen.It is calculated by subtracting total cholesterol from HDL 
cholesterol. Patients on statin therapy have relatively low LDL 
cholesterol but still a significant number of patients develop a second 
coronary or cerebrovascular event. In those patients other parameters in 
lipid profile such as triglycerides, low HDL cholesterol, & lipoprotein a 
and other remnant lipoproteins are important. The terminology non HDL 
cholesterol which includes all cholesterols other than HDL has a 
significant role in assessing the second risk for subsequent development 
of coronary or cerebrovascular events in statin treated individuals. The 
study was conducted to stress the importance of other parameters of lipid 
profile in bringing down the ischemic events. 
 
 
  
 
 
 
 
 
 
AIM 
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AIM 
 
The aim is to study if non HDL cholesterol has got significant role 
in assessing the risk of ischemic stroke on established coronary artery 
disease patients who were on atorvastatin therapy. 
. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
 
INTRODUCTION 
Atherosclerosis and its sequel are the leading causes of mortality in 
this world. With increasing prevalence of sedentary life habits and fast 
food culture early onset obesity are increasing in prevalence. Because of 
widespread awareness there is increasing use of statin therapy. But still 
the risk of coronary and cerebrovascular events has not come down. This 
study was conducted for analysing lipids beyond LDL. 
 Garg et al.,12 conducted a study to recognise the lipid parameter 
which has high levels of relation with both coronary artery disease and 
metabolic syndrome. They also had an aim of analysing the association of 
non HDL cholesterol and metabolic syndrome in particular among people 
residing in north India.  
Their study included: One hundred and thirteen Coronary artery 
disease patients & involved one hundred and forty non-coronary artery 
disease patients as controls between the ages thirty five and seventy five 
years. Both cases and controls were matched  for race and geography. 
Consent was obtained from both the controls and cases in writing. 
The study identified cases on the basis of history and standard 
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investigations. They measured Height, weight, waist and hip 
circumferences, blood pressures (systolic and diastolic) and lipid profile.  
The study concluded that Sixty nine among 113 (61.06%) of 
coronary artery disease patients and fifty two among one hundred and 
thirty (37.1%) of non-coronary artery disease patients had metabolic 
syndrome. 
 The CAD patients were identified based on their medical 
diagnostic history. Height, weight, waist and hip circumferences, blood 
pressures (systolic and diastolic) and lipid profile were measured for all 
the subjects. Age standardized presence of abnormalities in coronary 
artery disease was in the following order. Abdominal obesity had the best 
correlation followed by non-High density lipoprotein cholesterol which 
was followed by systolic blood pressure.  
The triglycerides, total cholesterol values and low density 
lipoproteins and HDL cholesterol had lesser significance and had 
decreasing value of correlation in that order. This specifies the role 
played by non-high density lipoprotein cholesterol by acting as a 
screening measure to identify patients with metabolic syndrome to assess 
their coronary vascular risk. 
Sigedel et al.,28 conducted a study to assess if non HDL cholesterol 
was an important measure in assessing CAD risk. Total cholesterol values 
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and low density lipoprotein cholesterol values are being used as 
correlative markers for many years. But many studies have reported non-
High density cholesterol as an important and easy measure, since non 
High density lipoprotein can be calculated by deducting High density 
cholesterol from total amount of cholesterol.  
It was a cross sectional study. Fifty one myocardial infarction 
patients and same number of controls clinical history electro and echo 
cardiography and enzyme analysis were used to diagnose myocardial 
infarction .Non HDL cholesterol values were obtained by deducting high 
density lipoprotein from total cholesterol. 
The results were statistically analysed. Forty two myocardial 
infarction cases had abnormal lipid profile in contrast to twenty of the 
controls. The study concluded that High density lipoprotein cholesterol 
had a better correlation followed by non-High density lipoprotein  
cholesterol. In this study non HDL cholesterol had a p value of o.o2 and 
low density lipoprotein had a p value of 0.05. The study concluded that 
HDL Cholesterol and non-high density cholesterol serve as a better 
measure than low density lipoprotein. 
 Vaccaro et al.,33.A study was conducted by Vaccaro et al to find 
the relationship between lifestyle changes advised by medical faculty 
&non high density lipoprotein cholesterol values. The study was done in 
 6 
United States among various. It collected data from national surveys. It 
concluded that minority population of UNITED STATES had received 
more dietary advice. Eighty per cent followed the advice. Those who 
were then practising weight reducing measures had low non high density 
cholesterol values. It stressed upon greater motivation to follow these 
goals persistently. 
  Kelley et al.,33. Their study used meta-analysis methods to 
evaluate non high density lipoprotein cholesterol values and diet and 
outdoor exercise. It included all randomised control trial in adults. On 
analysing various data the study concluded that there was no significant 
differences between the various studies and exercise and diet 
modifications caused reduction of non-high density lipoprotein 
cholesterol among various subjects. 
 Sniderman et al.,34. This study was conducted to analyse whether 
non high density lipoprotein cholesterol & apolipoprotein B were equal 
markers of atherosclerotic heart disease. This study got its data from the 
INTERHEART data base. 
The INTERHEART study is a case control study of acute coronary 
syndrome with samples taken from nine thousand three hundred and forty 
five cases and twelve thousand one hundred and twenty cases with data 
from fifty two countries.  In this study the apoprotein B and High density 
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lipoproteins were expressed in percentiles. Concordance was given by 
definition if apoprotein B contained normal cholesterol. It concluded that 
apoprotein B had better correlation value than non-High density 
lipoprotein though the difference was very minimal. 
 Rana et al.,27 Though lipid lowering goals are widely practised with 
various medications still there is significant risk of coronary artery 
disease. So they conducted a study was done to look in depth about other 
parameters in the lipid profile. They conducted a study to assess the role 
played by non-high density lipoprotein cholesterol. “The third adult 
treatment panel ATP 3” formulated some guidelines for the “US National 
Cholesterol Education Program”. This panel introduced non HDL 
cholesterol as a secondary goal for therapy among people when 
triglyceride was more than two hundred. Meta-analysis also confirmed 
the role of non-high density lipoprotein as an important goal. 
 Jones et al,2In“the EPIC-Norfolk prospective population study”, 
twenty one thousand four hundred and forty eight people not suffering 
from diabetes or coronary artery disease were followed up for eleven 
years. People who had high non HDL cholesterol had increased risk of 
coronary events in spite of low LDLl values. Next I would like to review 
the topic from books 
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DISEASE SPECTRUM 
Atherosclerosis affects varying circulatory compartments of the 
body but the manifestations are different. It affects the cerebral 
circulation and presents as transient ischemic events and stroke. It affects 
the coronary circulation and manifests as stable angina, unstable angina 
and myocardial infarction. It affects the renal arteries causing renal artery 
stenosis and it affects the peripheral vascular system causing claudication 
pain and even life threatening gangrene. All the atherosclerotic events are 
accelerated in a patient with diabetes mellitus. 
INITIATING EVENT IN ATHEROSCLEROSIS25 
Lipoproteins have high affinity for matrix extracellular proteins. 
When there is excess cholesterol they get deposited in the walls of 
arteries as fatty streak. They are the first macroscopic evidence of 
atherosclerosis. They generally adhere to tunica intima, the innermost 
layer of the arteries. They interact with glycosaminoglycan which causes 
difficulty in removal of these fatty streaks. They undergo various 
metabolic changes including oxidation which causes change in 
morphology and secures their place in the blood vessel.3 
Leukocyte Recruitment 
Once the fatty streaks are formed, there is ongoing inflammatory 
process and the release of various inflammatory mediators and the 
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recruitment of scavenger macrophages18 and monocytes into the lesion 
thus begetting further inflammation.4 
FOAM CELL FORMATION27 
The monocytes thus recruited engulf lipoproteins by receptor 
mediated endocytosis and accumulate lipid and become the giant lipid 
laden macrophages otherwise called foam cells. 
 Evolution of atherosclerotic plaque and its effects 
There are various complicating factors behind the development of a 
complex atheroma19. Many fatty streaks remain unmodified without 
causing any complication throughout life. 
Hypercholesterolemia causes LDL-C to accumulate in intima. 
Matrix interactions cause oxidative reactions of lipoproteins and 
inflammatory reactions are initiated. Altered lipoprotein particles actively 
promote inflammation. Chemo attraction by various chemokines  
including macrophage attractant protein cause increased entry of 
lipoproteins into the zone. 
As the lesion matures smooth muscle cells migrate superficially 
from the layer of media into the layer of intima where they play an active 
role in attracting further inflammatory particles and increasing the size of 
the lesion 
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ROLE OF HDL 
 Now the question how to remove cholesterol from fatty streak 
arises? This is done by the reverse cholesterol transport. The key 
molecule here is our HDL cholesterol. This HDL with the help of ATP 
binding cassette transporters receives cholesterol from the nascent cell 
and thus reduces the size of the atheroma and its effects. The gene 
responsible here is the ABCA gene. The mutations of this genes cause the 
Tangiers disease in which we have the orange color enlarged tonsils 
causing premature atherosclerosis. This is one of the diseases 
characterized by remarkably low HDL levels. 
The HDL thus loaded with cholesterol reaches the liver. In the liver 
it binds to the receptors responsible for scavenging which are the B 1 
receptors. Liver metabolizes the cholesterols into bile acids and are 
excreted through the bile. This pathway is called the reverse cholesterol 
transport and this is responsible for the anti atherogenic effect of HDL 
cholesterol and it thus receives its name the good cholesterol37 
Plaque natural course and termination in rupture20 
 
Plaques with very paper thin fibrous caps and huge lipid core 
material and a marked content of macrophages are more prone for 
rupture. On the other hand plaques with thick fibrous cap more smooth 
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muscles on the surface less amount of fats and macrophages are less 
likely to rupture and cause fatal events 
 
Factors involved in assessing risk of rupture of plaque24 
LDL particle dimension ,levels of homocysteine , high sensitive C 
reactive protein, phospholipase A2 measurements, fibrinogen content, 
myeloperoxidase levels are all important factors in assessing the risk of 
coronary events. With increasing number of markers being identified 
every day we tend to lose focus on the primary marker. Still the main 
events in assessing risk are family history, previous history,  serum lipid 
profile & glycemic status. These age old factors alone predict 95 % risk 
in all populations. 
“The list below includes the risk factors identified through the 
current “National Cholesterol Education Project32,33 Adult Treatment 
Panel III (ATP III).8,9 
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“Major Risk Factors modifying low density lipoprotein targets.12 
Smoking 
Hypertension JNC stage 1 and above 
Reduced HDL cholesterol level of less than forty mg/dl  
Diabetes 
Family history of  presence of coronary event 
Coronary event in men who have first degree relative less than 55 
years 
Coronary event in in females with 1st degree relative less than 65 
years 
Age (men more than forty five years &women  more than fifty 
five years) 
Obesity  
Sedentary habits 
Diet high in saturated fats 
Lipoprotein(a) 
Homocysteine 
Factors promoting thrombosis 
Factors promoting inflammation 
Abnormal blood sugar 
 
 
HDL cholesterol of more than 60 mg/dl is thought to be as a 
negative risk factor. When it is present we can remove one risk factor. 
When an individual has less than two risk factors the goal of LDL 
is <160 mg/dl. When there are two or more factors we have to calculate 
the risk of developing a coronary event in next ten years.  
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When the assessed risk is 20 % the target of Low density 
lipoprotein cholesterol is 130mg/dl. 
When the individual is suffering from diabetes or when there is 
evidence of atherosclerosis or when the assessed risk is more than 20 % 
then the target LDL cholesterol level is significantly low that is <100 
mg/dl. When the risk is markedly increased the goal is <70 mg/dl. 
 
LDL Level, mmol/L (mg/dl) 
Categorisation of risk Goal TLC initiation 
Pharmacological 
treatment 
Markedly increased <70 (70) (70) 
Acute coronary event 
with diabetes 
   
Increased risk <100 (100) 100<=100 
  optional 
target<70 
  
Moderately increased <100 130 130 
2or more risk factors    
Moderate  <130 130 160 
2or more risk factors    
Low <160 160 190 
0 or 1 risk factor    
 
The most important factors in achieving LDL goals are diet and exercise38 
According to ATP 3 guidelines when the level of LDL cholesterol 
in our patient is more than thirty mg/dl than his desired target we should 
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intervene him with drugs. When the patient’s triglycerides are elevated 
we should focus on the non HDL Cholesterol levels. This is simply done 
by deducting HDL cholesterol from total cholesterol values. The targets 
are slightly altered from the set points for LDL cholesterol by adding 
3omg/dl more. 
When LDL cholesterol levels have been lowered they don’t 
actually cause a decrease in size of atheroma but instead they give more 
stabilization to the atheroma and prevent them from breaking down 
easily. 
Statins the group of drugs that lower LDL cholesterol by inhibiting 
HMG CO A enzyme at night not only lower LDL levels but also has 
numerous additive effects on plaque morphology and physiology. 
Ezetimibe is a novel class of agent that decreases absorption of 
cholesterol from duodenum and jejunum. It acts on a cholesterol 
transporter on the enterocyte named as Niemann pick like protein 
NPC1L1. It acts as adjunct drug in lowering LDL levels and in achieving 
the target. The efficacy and safety of the drug has not been established. 
Beyond LDL 
Though LDL cholesterol is the most important factor in monitoring 
cardio vascular risk status and subsequent follow up of risk reduction, the 
case is not always so. 
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In spite of risk reduction with reduction of LDL cholesterol levels 
in certain sub group of patients the risk of atherosclerotic events remains 
high. Other factors like Apo lipoproteins, lipoprotein a and c reactive 
proteins14have a say. 
Non HDL cholesterol has a significant contribution in risk 
assessment and therapeutic goal monitoring especially when the 
triglycerides are high and in diabetes and in patients with metabolic 
syndrome. 
 
So we have to consider other details of the lipid profile to bring 
down the disease incidence. Though we have reduced the LDL 
cholesterol levels well with statin therapy we still see a lot of coronary 
events. Decreased HDL levels are considered in these cases.  HDL levels 
are inversely related to triglycerides. When the HDL levels are low the 
triglycerides level are high. So we are dealing with a dual problem. By 
losing weight and increasing physical activity we can greatly increase the 
HDL cholesterol and subsequently decrease the risk of coronary event. 
 Nicotinic acid or niacin is one drug which can significantly raise 
the high density lipoprotein levels. This has been proved by various trials 
and meta-analysis.  
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Flushing and pruritus are the major side effects associated with the 
consumption of niacin. This can be theoretically eliminated by the co 
administration of prostaglandin D receptor antagonist. This is under 
investigation and has not come to the markets. If this drug becomes 
successful it can eliminate the patient related factors in accepting niacin 
as a drug. 
Nuclear receptors agonists are being developed to raise HDL 
levels. When patients were given peroxisome proliferator & activator of 
receptor alpha and gamma PPAR agonists they did not have very good 
reduction of cardiovascular events. 
Paradoxically there was a significant increase in mortality. Hence 
these drugs are not recommended. Cholesteryl ester transfer protein 
CETP inhibitors also elevate high density lipoprotein levels. These agents 
are now under trial. 
Diabetes Mellitus and its association with Insulin Resistance& 
Metabolic Syndrome 
The leading cause of mortality in diabetes is complications due to 
atherosclerosis. With changing lifestyle and adaptation of unhealthy food 
practices these are considered as an epidemic now. 
Diabetic dyslipidemia, the term used to describe abnormal lipid 
profile in type 2 diabetes mellitus is the key factor behind the 
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atherosclerosis which occurs prematurely in diabetes. Though the LDL 
levels in diabetes are not significantly altered but the size of the particles 
and their density is condensed in diabetes which increases atherosclerosis 
risk Also these patients have reduced LDL and increased triglyceride 
levels. Hypertension is also commonly prevalent in diabetes and obese 
individuals with dyslipidemia. These factors have been well recognized 
by the ATP 3 guidelines. 
Pathophysiology of the metabolic syndrome 
 
 
Free fatty acids  are being liberated in large quantity out from an 
enlarged adipose tissue structure when they reach the liver they cause 
increased production of glucose by gluconeogenesis and triglycerides and 
results in the synthesis of VLDL. It also causes lipoprotein abnormalities 
like decrease in low density lipoprotein and increase in high density 
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lipoprotein. Free fatty acids cause reduction in sensitivity of muscle to 
insulin and their glucose uptake. When the glucose levels are high they 
stimulate the pancreas and cause release of insulin resulting in 
hyperinsulinemia.  Hyperinsulinemia causes increase of sodium transport 
promoting sympathetic nervous system activity and also causes release of 
fatty acids as substrates for gluconeogenesis. Since the environment is 
ultimately proinflammatory they cause increase in insulin resistance. 
Interleukin 6 and tumor necrosis factor secreted by macrophages also 
cause increase in insulin resistance and elevation of triglycerides and 
release of free fatty acids. They also increase gluconeogenesis, very low 
density lipoprotein production and increase in insulin resistance by 
skeletal muscle, fibrinogen produced by liver and plasminogen activator 
inhibitor 1 produced by adipocytes cause the state to turn prothrombotic. 
Increased production of C-reactive protein by the liver also adds to the 
cause. Decreased synthesis of anti-inflammatory factors & the cytokine 
adiponectin which sensitizes insulin are associated with high prevalence 
of metabolic syndrome. 
Overweight is a significant component of the metabolic syndrome. 
But what has a greater significance value is the abdominal obesity. So 
abdominal obesity is the single most measurement in assessing the 
metabolic syndrome. So we can identify majority of patients with 
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metabolic syndrome by measuring their abdominal girth. A simple inch 
tape is all that is required. 
 
diagnosis of  Metabolic Syndrome Any 3 Factors 
 
Risk Factor Cut off point 
Central obesity   
 Male {waist circumference}  >=102 cm  
 Female >=88 cm 
 Triglycerides >=150 mg/dl 
High density lipoprotein   
 Male <40 mg/dl 
  Female <50 mg/dl 
Blood pressure 130/85 mmHg 
blood glucose while fasting >110 mg/dl 
 
 
Some patients especially men though they have only slight increase 
in waist circumference have other points in favour of the detection of 
metabolic syndrome. They have strong genetic influence for the 
development of metabolic syndrome. They should be advised diet and 
lifestyle changes 
The main goal in the therapy of metabolic syndrome is proper 
education and counselling regarding the hazards of faulty diet habits and 
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physical inactivity. Half an hour of physical activity a day increases their 
life span by 6 to 7 years. The ATP 3 guidelines also stresses upon these 
factors. 
Establishing proper glycaemic status reduces micro vesicular 
complications more than macro vesicular complications of diabetes. 
Hence early detection of diabetes and following patients periodically is 
important. It may even result in adverse events. So the ultimate goal is in 
correction of diabetic dyslipidaemia and other factors.. 
Multiple drug trials are being conducted keeping in mind the 
specific dyslipidaemia problems of diabetes. Statin therapy has been 
shown to have very high benefit beyond doubts. Other factors beyond 
tight glycaemic control are being looked upon. 
Since the benefit of HMG CO A reductase inhibitors for diabetic 
populations are proved by meta-analysis. The American diabetic 
association recommends statins to all patients with total cholesterol above 
one hundred and thirty five. 
Metformin is the only oral hypoglycaemic agent which is found to 
be cardio protective. Statins are not useful in chronic kidney disease 
especially in end stage. 
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Issues in assessing risk 
A large number of markers of coronary event risk have been 
identified in recent years. Markers estimated by using peripheral arterial 
blood include size of low density lipoprotein particles & levels of blood 
homocysteine, Lipoprotein a, fibrinogen, C reactive protein, plasminogen 
activator inhibitor protein 1, tissue myeloperoxidase& lipoprotein related 
phospholipase A2. 
 
But still there is no substitute for careful history taking and analysis 
of serum lipid profile and fasting blood glucose. 
With the existing clinical data we are not in a position to 
recommend imaging studies as a screening test in detecting underlying 
disease. Such methods include the usage carotid Doppler to study carotid 
intima media thickness, calcification, MR angiography and CT 
angiography. If these tests are used universally the patients may panic and 
this may increase the economic burden of the society 
Use of these investigations requires further supportive evidence in 
order to be practiced. 
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ISCHEMIC HEART DISEASE 
Pathophysiology 
The basic pathophysiology in understanding a myocardial ischemia 
is demand supply mismatch. That is the demand between oxygen supply 
and coronary blood flow.  
Whenever there is any demand for oxygen it is the work of 
myocardium to ensure that there is availability of adequate oxygen rich 
blood to the tissues in demand. When this does not happen that part of 
myocardium will suffer from ischemia. 
The coronary circulation is regulated by the hearts oxygen needs 
on a minute by minute basis. This is achieved by the ability of coronary 
bed to greatly alter its resistance so that the myocardium always has a 
very high & almost stable fraction of oxygen. Ordinarily, intra 
myocardial resistance vessels have a greater capacity for dilation.  
During exercise and emotion the heart needs to pump at a faster 
rate resulting in great changes in its oxygen need. This is accomplished 
by the change in vascular resistance to a great extent. This is termed 
metabolic regulation of coronary vascular bed. 
The change in resistance of coronary vascular bed to changes in 
blood pressure that happens several times in a day is called auto 
regulation. Since the lumen of arteries is narrowed in atherosclerosis 
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when there is an increase in demand the required oxygen supply cannot 
be met. This results in ischemia. When there is severe obstruction even 
the blood supply at rest is reduced.  
This results in rest angina. When spasms of vessels occur as in 
prinzmetals angina the blood supply is reduced also resulting in ischemia. 
Aortitis results in narrowing of the ostia and reduction in blood supply. 
Congenital anomalies like anomalous origin of left anterior descending 
artery from pulmonary artery can lead to myocardial ischemia in infancy 
which is a rare cause. 
Coronary Atherosclerosis 
Epicardial coronary arteries are the most common site for the 
development of atherosclerosis. Plaque formation and later rupture at 
segments is the cause of epicardial coronary vessel narrowing. When the 
rupture of plaque occurs platelets are recruited and activated and then the 
coagulation cascade is initiated and activated. 
All this leads to accumulation of numerous fibrin strands at the site 
of injury. The thrombi thus formed also attract red blood cells and grows 
in size and can cause total occlusion of the vessel. 
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Implications of Ischemia 
When the demand is not met due to critical occlusion various 
pathological, biochemical and electrophysiological alterations take place 
in the myocardial cell. All these changes usually occur at one particular 
vessel. Usually multiple vessels are not affected at the same time.  
The segment that is affected causes that portion of myocardium to 
perform with decreased contractility or absent contractility or bulging or 
dyskinetic segment. All these ultimately lead to decrease in cardiac pump 
activity and cardiac output. 
The sub endocardium is relatively receiving little blood supply 
when compared to the subepicardium. So even small occlusions in the 
sub endocardium cause great damage decreasing output function. 
Ultimately left ventricle failure can occur and papillary dysfunction and 
mitral regurgitation also happen as sequel. When these events happen 
transiently they cause angina. But total occlusion results in permanent 
scarring. 
Treatment of dyslipidemia 
The treatment of dyslipidemia is considered as the ultimate goal for 
freedom from angina, decreased necessity for revascularization, & 
decrease in incidence of cardiac ischemia and death. The regulation of 
lipids is reached by combining diet less in saturated and trans- fatty acids 
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work up, and losing weight. HMG-CoA reductase inhibitors are an 
indispensable part of treatment & can lessen LDL cholesterol (25–50%), 
increase high density lipoprotein cholesterol (5–9%) and lessen 
triglycerides (5–30%). Significant treatment effects due to statins on 
coronary events and outcome is achieved independent of the low density 
lipoprotein 36 level before treatment. Fibrates or niacin is given in order to 
increase high density lipoprotein levels & lessen triglycerides. Trials have 
shown that lipid lowering has benefited all classes of people. 
The major issue is the patient compliance with these behavioral life 
style modifications and the physician often underestimates his role in 
motivating and educating patients to practice it not for days or months but 
lifelong. Patients also tend to discontinue treatment. The dropout rate is 
more than 50 % stressing upon patients education and motivation. It is the 
duty of the physician to ensure that patients come for constant follow up. 
 
TREATMENT OF DYSLIPEDIMIA39 
So considering the importance of dyslipidemia in increasing the 
life span of individuals worldwide many drug companies have invested 
much on this aspect of pharmacology. These drugs give benefit to 
individuals overall spectrum of cholesterol levels, mainly decreasing the 
low density lipoprotein values. 
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The Expert Panel 2002 recommends that the lipid modifying drugs 
should be initiated when an individual has less amount of blood HDL 
levels even though his LDL levels may not be high enough to achieve the 
target of starting lipid lowering therapy in the event of him having a risk 
factor .Heart Protection Study Collaborative Group study has indicated 
that starting drugs on patients with low HDL and average LDL has 
reduced the incidence of risk of CAD in in these patients by 30 %. 
 
Plasma Lipoprotein Metabolism 
Lipoproteins are molecules that have both lipids and proteins. The 
lipid constituents consist of free & esterified cholesterol & triglycerides 
and some include phospholipids also. The protein components are called 
Apo lipoproteins or shortly apoproteins. They give structural stability to 
the lipoproteins. They also serve as ligands when lipoprotein interacts 
with its receptors or serve as cofactors in enzymatic processes regulating 
metabolism of lipoproteins. 
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Chylomicrons 
 
 
 
The body synthesizes chylomicrons by the absorption of 
triglycerides and cholesterol when absorption takes place after 
consumption of food from the small intestine. 
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This absorption of cholesterol and also various plant sterols from 
the intestine is achieved by the mediation of Niemann Pick like 1 protein 
thatis the place where the drug ezetimibe acts, which inhibits cholesterol 
absorption. Dietary cholesterol undergoes esterification with the help of 
the enzyme acyl coenzyme A (cholesterol acyltransferase) (ACAT). This 
enzyme is present in the intestine and in the liver the sites of esterification 
of free cholesterol before the assembly of lipoproteins rich in 
triglycerides take place. These are the chylomicrons & very-low-density 
lipoproteins. 
 
The proportion of triglycerides and cholesterol is 10 or more. In 
patients with lipids within normal limits chylomicrons are found within 
plasma for three to 6 hours after ingestion of food rich in fat.  
 
When the individual fasts for 10 to 12 hours chylomicrons 
disappear from the blood. 
The apolipoproteins of chylomicrons consists of apoB-48, apoA-I, 
and apoA-IV. These are synthesized in the intestinal epithelial cells and 
few of them are derived from apoE and apoC-I C-II, and C-III when the 
chylomicrons are secreted into the lymph and enter the plasma. 
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Chylomicron Remnants 
When the lipoprotein mediates the removal of the triglycerides 
from the chylomicrons, the remnants, have all of the remaining 
cholesterol obtained from food. 
They remove themselves from the capillary surface and enter the 
liver and are removed by the liver with the help of Apo E. 
 
Very-Low-Density Lipoproteins 
 
 
When there is an increase in the flux of the free fatty acids in the 
liver or increased triglyceride content the liver decides to produce more 
very low density lipoproteins.  
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The size of these particles range between 40 to 100 nm in diameter 
& are large enough to lead to plasma turbidity. However unlike 
chylomicrons, these particles do not float spontaneously on the top of a 
tube containing undisturbed plasma.ApoB-100, apoE, and apoC-I, C-II, 
and C-III are synthesized by the liver cells and incorporated into VLDL. 
If triglycerides cannot synthesize VLDL, the newly synthesized apoB-
100 is degraded by liver cells.  
 
Low-Density Lipoproteins 
 
The LDL particles are produced by the degradation of intermediate 
density lipoprotein. They have a t1/2 of 1.5 to 2 days. That is why they 
have more plasma concentration than VLDL and IDL. In Individuals not 
suffering from hypertriglyceridemia, 2/3rds of plasma cholesterol is 
present in low density lipoprotein cholesterol. ApoB-100 is the only Apo 
protein of LDL, and it is the ligand that binds Low density lipoprotein 
and its receptor molecule. 
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High-Density Lipoproteins 
The metabolism of HDL is said to be complex because of the 
various process through which High density lipoprotein particles are 
altered in the compartment of plasma and by mechanism of synthesis of 
HDL. ApoA-I is the major HDL apoprotein, & its concentration in 
plasma is considered a good predictor of cardiovascular risk even better 
than high density lipoprotein cholesterol level. 
 
Lipoprotein a 
Lipoprotein a has a low density lipoprotein particle that has another 
Apo protein along with apoB-100. 
 
 
 
 Targets Initiation of change in 
lifestyle 
pharmacological Therapy 
Initiated for 
RISK 
CATEGORY 
LDL-  TC:HDL-
C 
LDL-C  TC:HDL-C LDL-
C 
 TC:HDL-C 
CHD or equivalent <100 and <3.5 100 or 3.5 100 or 3.5 
2or more risk 
factors 
<130 and <4.5 130 or 4.5 130 or 6.0 
0or1 risk factor <160 and <5.5 160 or 5.5 160 or 7.0 
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Guidelines Based on LDL-cholesterol and Total cholesterol: HDL-
C Ratio for treating Low HDL-cholesterol Patients 
Plasma lipid level classification 
 
Total cholesterol   
 <200 mg/dl Optimal 
 200–239 mg/dl Slightly increased 
 240 mg/dl High 
High density lipoprotein   
 <40 mg/dl Low (<50 mg/dl for females) 
 >60 mg/dl High 
Low density lipoprotein  
 <70 mg/dl Ideal for high risk 
 <100 mg/dl Ideal 
 100–129 mg/dl Almost ideal 
 130–159 mg/dl Slightly increased 
 160–189 mg/dl High 
 190 mg/dl significantly high 
Triglycerides   
 <150 mg/dl Normal 
 150–199 mg/dl Slightly increased 
 200–499 mg/dl High 
 500 mg/dl Significantly increased 
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STATIN THERAPY 
The statins are the most effective drugs with less adverse events 
profile for treating patients suffering from dyslipidemia. 
Statins act by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A 
reductase, by competitive inhibition which acts as a catalyst in an early, 
rate-limiting step in the synthesis of cholesterol.  
Doses in the high range of the recent drugs with increased potency 
(e.g., atorvastatin and simvastatin) also decrease triglyceride levels due to 
elevated VLDL levels. 
Mechanism of action: 
Statins cause reduction in cholesterol levels by decreasing 
synthesis of cholesterol by hepatocytes which causes increase in the 
expression of low density lipoprotein receptor gene. As free cholesterol 
content within hepatocytes is reduced, membrane bound SREBPs are 
cleaved by a protease and are trans located into nucleus. The transcription 
factors bind to the sterol responsive element of the low density 
lipoprotein receptor gene, increasing transcription & causing increase in 
the synthesis of low density lipoprotein receptors. Degradation of LDL 
receptors also is reduced. 
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Triglyceride Reduction by Statins 
Triglyceride levels >250 mg/dl are brought down significantly by 
statins, & the % reduction achieved is like that of the % reduction in low 
density lipoprotein cholesterol. Similarly, hypertriglyceridemia occurring 
in patients who consume high doses of the best potency statins 
(simvastatin and atorvastatin, 80 mg/day; rosuvastatin, 40 mg/day) reach 
about 40% decrease in LDL-Cholesterol and also the same results are 
seen in triglyceride values. 
 
Effects of Statins on HDL-C Levels 
Many studies conducted for statin effectiveness have particularly 
eliminated HDL cholesterol levels. While analyzing patients with 
increased LDL-Cholesterol levels & near normal HDL Cholesterol values 
(40 to 50 mg/dl in males & 50 to 60 mg/dl in females), an elevation in 
HDL Cholesterol of 5 - 10% has been reported, in spite of the variations 
in the dose of statin employed. 
But the case is not the same when the HDL cholesterol value is 
low. The reports are variable and need further study. 
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Potential beneficial effects apart from LDL lowering: 
Statin treatment increases endothelial synthesis of nitric oxide 
which has beneficial action by causing vasodilatation. 
Statins affects stability of plaque in many methods. Statins cause 
inhibition of monocyte entry into the site. 
Statins decrease the coronary risk & high values of CRP which is 
considered an important marker for inflammation in spite of decreasing 
cholesterol. 
Change in morphology of LDL by oxidation has a significant effect 
in affecting the uptake of lipoproteins by macrophages and also causing 
cytotoxic effects within lesions. 
Statins decrease assembly and aggregation of platelets. 
 
Bile Acid Sequestrants 
The two well accepted bile acid sequestrants also widely called 
resins are cholestyramine & colestipol. They are the oldest among 
hypolipidemic class of drugs & they have safe adverse effect profile as 
they do not have their absorption at the small intestine. They can be used 
for patients between 11 to 20 years of age. As statins are good as 
monotherapeutic agents, they are commonly used as 2nd line agents when 
statin therapy cannot attain its LDL lowering target successfully. 
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Niacin  
Niacin (pyridine-3-carboxylic acid) is one of the age old 
dyslipidemic classes of drugs, which has its say on all lipid parameters. In 
fatty tissues, niacin decreases the lipolysis of triglycerides with the help 
of hormone sensitive lipase which decreases entry of free fatty acids into 
the liver and causes reduction of synthesis of triglycerides by the liver. 
 
Fibric Acid Derivatives 
Fibrates bind to PPAR which is expressed predominantly in the 
liver and brown adipose tissue & also to a certain degree in kidneys heart 
& skeletal muscle. Fibrates cause decrease in triglycerides by means of 
PPAR through increase in fatty acid oxidation increase in lipoprotein 
lipase synthesis and decrease in expression of lipoprotein lipase. Any 
increase in lipoprotein lipase levels will increase the removal of 
triglyceride rich lipoproteins. 
Decrease in synthesis of apoC-III by the liver, acts by inhibiting 
lipolytic processing & receptor mediated clearance, will increase the 
removal of very low density lipoprotein. Fibrates mediated enhancement 
in HDL Cholesterol levels are because of PPAR stimulation of apoA-I 
and apoA-II expression, that enhances High density lipoprotein 
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cholesterol levels. Fenofibrate is more successful in increasing high 
density lipoprotein levels than gemfibrozil. 
 
Ezetimibe and its inhibition of uptake of cholesterol from food 
Ezetimibe is the 1st drug approved to decrease total and low 
density lipoprotein levels that decreases absorption of cholesterol by the 
intestinal enterocytes. It decreases low density lipoprotein levels by about 
20 % and is used commonly as an add on therapy along with statins. 
 
Non HDL cholesterol 
It is calculated by deducting high density lipoprotein from total 
cholesterol. It includes VLDL, LDL, IDL ,VLDL remnants, chylomicron 
remnants and other remnant lipoproteins. 
 
Significance 
The decrease in coronary vascular risk by causing reduction in 
low-density lipoprotein cholesterol levels is widely accepted and low 
density lipoprotein Cholesterol is the ultimate goal in lipid lowering 
therapy. But this is not the case in all patients. Many patients do not have 
high LDL cholesterol levels. There is a increase in recognition of non-
high density lipoprotein cholesterol as a significant predictor of 
cardiovascular risk. Non high density lipoprotein cholesterol can be 
 38 
attained by deducting HDL cholesterol from total cholesterol and 
includes all components of cholesterol found within the atherogenic 
lipoprotein particle. Non HDL Cholesterol is very important in some 
subgroups, like those with diabetes, who are suffering from dyslipidemia 
which is marked by low HDL cholesterol levels & increased triglyceride 
levels. Measuring non HDL cholesterol is expected to capture the risk 
associated with triglyceride rich particles. Non HDL Cholesterol was 
found definitely to correlate with coronary artery disease severity and 
progression and also as a predictor of cardiovascular disease mortality. 
Treatments that target non HDL Cholesterol include lifestyle measures 
and drug therapy. Statins as a group except rosuvastatin and simvastatin 
do not significantly reduce non HDL cholesterol. Fibrates as a class of 
drugs have got significant role in decreasing triglycerides and non HDL 
Cholesterol. Further non HDL Cholesterol is a calculated value using 
total cholesterol and HDL both of which are got from direct 
measurements whereas LDL cholesterol is a predicted value using 
FRIEDWALDS equation. Non HDL cholesterol includes all the 
atherogenic particles in the lipid profile. Hence its considered to have 
a superior predictive value. 
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National cholesterol education program 
LDL & Non High density lipoprotein Goals for3 Risk subdivisions 
Risk subcategory LDL target Non-HDL target 
Coronary risk 
equivalent, diabetes 
included 
 
<100mg/dl 
 
<130mg/dl 
Two or more Risk 
Factors 
<130mg/dl <160mg/dl 
 0 or 1RiskFactor <160mg/dl <190mg/dl 
 
Non HDL Cholesterol levels & cardiovascular Risk assessment 
Numerous trials conclude that a strong relationship exists between 
non HDL Cholesterol and atherosclerosis, even in youth. When autopsy 
was conducted in young deaths and analysed it was concluded that non 
HDL Cholesterol was related to the presence of fatty streaks and elevated 
lesions in the coronary arteries. It was proved that there was strong 
relationship between the degree of atherosclerosis & HDL cholesterol 
levels and non-high density lipoproteins. 
The Cholesterol Lowering Atherosclerosis Study which was done 
15 years ago undoubtedly established a clear association between non 
HDL and coronary vascular disease risk.  This was a randomized 
placebo-controlled trial of colestipol along with niacin treatment in males 
who had prior coronary bypass surgery. This study concluded that, non 
HDL Cholesterol was undoubtedly the best predictor of all the changes in 
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degrees of coronary disease in males who were not on treatment with 
medications to lower cholesterol. Another study named as “The Lipid 
Research Clinics Follow-up Study” was done to analyse if non HDL 
Cholesterol predicted cardiovascular disease mortality in older age groups 
(40 to 64 years) who did not suffer from coronary artery disease at 
baseline. It concluded that in men both LDL-C and non–HDL-C had 
same predictive values while in females non–HDL-Cholesterol was a 
better predictor. 
“Non-HDL cholesterol is a surrogate marker for all the major 
atherogenic lipoproteins.” 
In order to state otherwise, non-high density lipoprotein cholesterol 
may be a better predictor of cardiovascular risk than low density 
lipoprotein cholesterol or triglycerides in certain patient populations, 
since it reflects the total serum cholesterol carried by all of the potentially 
atherogenic lipoproteins— LDL, VLDL, IDL, Chylomicron remnants 
and other remnant lipoproteins. And also as it is calculated from total 
cholesterol and high density lipoprotein cholesterol, both of which are got 
by direct measurements. It does not get affected by the triglyceride level 
and we need not collect the specimen in fasting. 
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CEREBROVASCULAR ACCIDENT 
The common terminology is the stroke, defined as the sudden onset 
of a non convulsive, focal neurologic deficit. 
 
PATHOPHYSIOLOGY OF ISCHEMIC STROKE 
 
 
A. Diagram to demonstrate the 3 major mechanisms responsible 
for ischemic stroke:  
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1. An intracranial artery occluded because of an embolus that has its origin 
at a distant site. Examples are cardiogenic sources such as atrial 
fibrillation or artery-to-artery emboli from carotid atherosclerotic plaque, 
most commonly occluding larger intracranial vessels 
2. In situ thrombosis of an intracranial vessel, typically affecting the small 
penetrating arteries that arise from the major intracranial arteries 
3. Hypoperfusion due to flow-limiting stenosis of a major extracranial (e.g., 
internal carotid) or intracranial vessel, commonly causing “watershed” 
ischemia. 
B and C. Diagram and reformatted CT angiogram of the common, 
internal, and external carotid arteries. High-grade stenosis of the internal 
carotid artery, which may be associated with either cerebral emboli or 
flow-limiting ischemia,  
 
PHYSIOLOGY 
The adult brain, measures around 1500 g or 2% of the total body 
weight, and needs about 150 g of glucose and 72 L of oxygen every 24 
hours without any interruption.  
This amounts to 20% of the body’s total oxygen consumption. 
Since the brain cannot store the substances, severe affect in functioning 
occurs after only a few minutes of absence of either the oxygen or 
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glucose or their reduction below critical levels. At rest, each cardiac 
contraction gives about seventy millilitre of blood into the ascending 
aorta. Ten to fifteen mL is provided to the brain. Every minute, about 350 
mL flows through each internal carotid artery, and 100 to 200 mL 
through the vertebra basilar system, to achieve a total cerebral blood flow 
of 50 mL/min per 100 g. 
 
Features 
Premonitory stroke symptoms are not always found; fewer than 
20% of stroke patients have a prior TIA. Focal premonitory symptoms, 
when present, usually predate infarction rather than haemorrhage.  
When they occur, they may be so nonspecific that they are not 
recognized as signs of an impending stroke. Within 90 days after a TIA, 
the risk of stroke has been reported to be as high as 10% to 20%, and 
nearly half of these patients will have their stroke in the first  2 days after 
the TIA. 
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“Risk factors for stroke” 
   Number Needed to Treata 
Risk Factor Relative Risk Relative Risk Reduction with Treatment 
Primary 
Prevention 
Secondary 
Prevention 
Hypertension 2–5 38% 100–300 50–100 
Atrial fibrillation 1.8–2.9 68% warfarin, 21% aspirin 20–83 13 
Diabetes 1.8–6 No proven effect   
Smoking 1.8 50% at 1 year, baseline risk at 5 years' postcessation   
Hyperlipidemia 1.8–2.6 16–30% 560 230 
Asymptomatic carotid 
stenosis 2.0 53% 85 N/A 
Symptomatic carotid 
stenosis (70–99%)  65% at 2 years N/A 12 
Symptomatic carotid 
stenosis (50–69%)  29% at 5 years N/A 77 
 
Risk factors for ischemic stroke 
Modifiable and non-modifiable risk factors for ischemic stroke 
have been identified and include age; gender; race/ethnicity; heredity; 
hypertension; cardiac disease, particularly atrial fibrillation; diabetes 
mellitus; hypercholesterolemia; cigarette smoking; and alcohol abuse, 
hypercoagulable states and patent foramen ovale. 
Brain Infarction17 
Brain or neuronal dysfunction occurs at cerebral blood flow levels 
of below 50 mg/dL, and irreversible neuronal injury is initiated at levels 
below 30 mg/dL. Both the degree and duration of reductions in cerebral 
blood flow are related to the likelihood of sustained neuronal injury. 
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When blood supply is completely interrupted for 30 seconds, brain 
metabolism is altered. After 1 minute, neuronal function may cease. After 
5 minutes of interruption, anoxia initiates a chain of events that may 
result in cerebral infarction; however, if oxygenated blood flow is 
restored quickly enough, the damage may be reversible, as with a TIA. 
The following steps occur in the evolution of an infarct: (1) local 
vasodilatation and (2) stasis of the blood column, with segmentation of 
the red cells, followed by (3) oedema and (4) necrosis of brain tissue. The 
earliest ischemic changes are visualized by increased water content in 
diffusion-weighted MRI while with time, an infarct is well delineated by 
fluid-attenuated inversion recovery (FLAIR) and T2-weighted changes on 
MRI. 
Large-vessel Atherosclerotic Infarction 
Atherosclerotic plaque that occurs at the site of a bifurcation in any 
of the larger vessels will cause stenosis progressively, as the final large 
artery occlusion is because of thrombosis in the lumen that is narrowed. 
Arteriosclerotic plaques can originate at any site along the carotid artery 
& the vertebrobasilar system. Yet the most common sites are the 
bifurcation of the common carotid artery into the external and internal 
carotid arteries, the origins of the middle and anterior cerebral arteries, 
and the origins of the vertebral from the subclavian arteries. 
 46 
An atherosclerotic stenosis or occlusion may also lead to a cerebral 
infarction through an embolic mechanism. In this case, emboli arising 
from the proximally situated atheromatous lesions occlude otherwise 
healthy branches located more distally in the arterial tree. 
 
Small-Vessel Lacunar Infarction 
This particular subtype has various named entities, because of 
ischemia confined to the territory of a single vessel. They reflect arterial 
disease of penetrating vessels which supply the internal capsule, basal 
ganglia, thalamus, corona radiata, and paramedian regions of the 
brainstem. Disagreements exist about the pathogenesis of lacunar 
infarcts; some studies consider the use of the term lacunae to describe 
size and location, without indicating a specific pathology. The 
pathologies of only a handful of such infarcts have been studied by serial 
section, and only a few of those studies have documented a tiny focus of 
microatheroma or lipohyalinosis stenosing one of the deep penetrating 
arteries. The arterial damage is generally due to long-standing 
hypertension or diabetes mellitus. 
 
  
 
 
 
 
 
 
MATERIALS AND 
METHODS 
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MATERIALS AND METHODS 
 
This study was done in Mahatma Gandhi Memorial Government 
hospital from the period of May 2010 to December 2012. 
Consent was obtained from all participants 
 
Inclusion criteria 
Patients on established coronary artery disease who were on 
atorvastatin therapy 10 mg for more than 1 year, who developed an 
ischemic stroke evidenced by CT scan or MRI within 5 years of 
occurrence of the first coronary event. 
 
Exclusion criteria 
Age less than 40 years. 
Patients on irregular statin therapy. 
Patients with chronic kidney disease. 
Patients with chronic liver disease 
Patients who had poor left ventricle function 
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STUDY DESIGN 
Number of study groups : two 
Group 1 CASES: 50 patients with a history of coronary artery 
disease with ECG or ECHO confirmation and who were on regular 
atorvastatin therapy 10 mg daily for more than one year who developed a 
cerebrovascular event in the form of ischemic stroke with CT or MRI 
Brain evidence within 5 years of occurrence of the first coronary event 
were included in the study.  
Group 2 CONTROLS: A suitable control of 50 patients matching 
age, sex, smoking, alcohol and diabetes who had coronary artery disease 
and were also on atorvastatin therapy 10 mg for more than 5 years were 
included. These patients should have normal CT brain and no prior 
history suggestive of transient ischemic attacks. 
Study size: 50 
Study type: case control study 
The age ranges from 40 to 80 and the study included both sexes. 
The study was approved by institutional ethics committee. The risk 
factors associated with, both modifiable like cigarette smoking, alcohol 
consumption, hypertension, diabetes mellitus and obesity (BMI) and non- 
modifiable like age, sex, family history was taken into consideration. The 
risk factors smoking and alcohol were found out by careful history taking. 
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The risk factors DM and HT were detected by past medical history and 
laboratory routine investigation and BP measurement. 
Total cholesterol HDL Cholesterol and triglycerides were 
measured in overnight fasting of 10 hrs. at 7 a.m. in the morning using 
Hitachi 704 Analyser . Low density lipoprotein Cholesterol was 
calculated by the FRIEDWALD formula LDL-chol = total chol - HDL-
chol - Triglycerides/5 which is internationally accepted. Non HDL 
cholesterol was calculated by deducting HDL from total cholesterol. Both 
cases& controls were established coronary artery disease with ECG and 
ECHO confirmation. 
All the basic blood investigations were done and their body mass 
index was calculated and the presence of metabolic syndrome was 
analysed. Those who had elevated renal parameters or abnormal liver 
function tests were excluded from the study. 
 
Statistical analysis 
  Descriptive statistics were used to calculate the frequency, 
mean, median, and standard deviation. For all normally distributed 
variables, unpaired t test was used to determine the significant mean 
difference in groups. Chi squared test was used to compare discrete 
variables. 
  
 
 
 
 
 
 
RESULTS AND ANALYSIS 
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RESULTS AND ANALYSIS 
50 patients with a history suggestive of coronary artery disease 
with ECG or ECHO confirmation and who were on regular atorvastatin 
therapy 10 mg for more than one year who developed a cerebrovascular 
event in the form of ischemic stroke with CT or MRI Brain within 5 years 
of the occurrence of the first coronary event were included in the study. A 
suitable control of 50 patients eliminating age, smoking, diabetes, 
hypertension, alcohol consumption were included. 
 
Age 
AGE RANGE NUMBER OF PERSONS 
40-49 1 
50-59 9 
60-69 25 
70-79 15 
TOTAL 50 
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Age distribution 
 
In our study the mean age of the population was 66.4 years .The 
majority of patients (25) in our study were in the age group 60 to 69 
years.  
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Sex 
SEX No. OF CASES 
MALES 29 
FEMALES 21 
TOTAL 50 
 
Sex distribution 
 
 
 
Out of the 50 cases 29 were males and 21 were females. 
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AGE SEX RATIO 
AGE MALES FEMALES RATIO 
40-49 1 O 0% female 
50-59 6 3 50% FEMALE 
60-69 16 9 56.25% FEMALE 
70-79 6 9 150 %FEMALES 
TOTAL 29 21  
 
 
 
 
 
 
 
 
Age sex ratio 
The age sex ratio indicates that females had later onset of vascular 
events compared to males 
There were 29 males & 21 females. Their average age  was 67.72 
years; females were somewhat elder to their male counterparts. Most of 
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them belonged to the 60-69 years age group (50%). Youngest male was a 
45 years old electrician, who had hyper homo cystinemia. He also had 
evidence of peripheral arterial disease. He had strong family history of 
Coronary and cerebro vascular disease. 
 
FAMILY HISTORY 
In our study 38 (74%) CAD patients who developed CVA had 
positive history of ischemic events in family and 28 (56%) of the 
controls who were CAD patients and did not develop CVA had positive 
family history. Chi squared equals 8.117 with 1 degrees of freedom.  
 The two-tailed P value equals 0.0044 
 By conventional criteria, this difference is considered to be very 
statistically significant. 
 CAD WITH 
CVA 
CAD WITHOUT 
CVA 
+ FAMILY HISTORY 38 28 
no FAMILY HISTORY 12 22 
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Incidence of CAD with CVA in patients with family history 
RelativeRisk= 
   Incidence of CAD with CVA in patients with negative history 
 
 
  =  a/(a+b)÷c/(c+d) 
= 1.6 
 
Thus a positive family history can be associated with a 1.6 fold 
increase in the risk of developing CVA in established CAD patients. 
 It is important to remember that earlier onset of both coronary and 
cerebrovascular events were observed in patients with positive family 
history. 
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Smoking 
Total Smokers Nonsmokers 
50 males females males Females 
 20 0 9 21 
 
 
 
Out of the 50 patients 20 were smokers which accounts to 40 %.All 
the 21 females were nonsmokers. But 17 of the females were exposed to 
passive smoking.  
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Alcoholism 
Total Alcoholics Non alcoholics 
 Males females males Females 
 19 1 10 20 
 
 
 
Out of the 50 patients 20 were alcoholics which accounts to 40 %. 
Out of the 21 females one was an alcoholic. She works as a cleaner in a 
bar shop and developed the habit of tasting the left over wines and 
became addicted to it. 
The controls were matched for smoking and alcoholic. Except that 
the lone female alcoholic could not be suitably matched. 
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DIABETES MELLITUS 
 DIABETES NON DIABETICS 
50 MALES FEMALES MALES FEMALES 
 10 6 19 15 
TOTAL 16 34 
 
 
 
 
Out of the 50 patients studied 16 were known diabetes patients on 
treatment accounting to 32% of cases. 
The controls were matched for diabetes. 
 59 
SOCIO ECONOMIC STATUS 
50% of patients belonged to lower socio economic group, while 
40% were from middle income group and only 10% were from upper 
group. 
Existence of coronary artery disease in the lower socio economic 
group of people in the urban areas has changed considerably due to 
change in lifestyle. The more number of patients in low socio economic 
group could be because of more number of low socio economic group 
people visiting government hospital in general. 
 
Low socioeconomic 
group 
Middle socio 
economic group 
High socio economic 
group 
 
25 
 
20 
 
5 
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HYPERTENISON 
Out of the 50 patients 36% were hypertensive. The controls were 
matched for hypertension. 
 
 
TOTAL HYPERTENSIVES NONHYPERTENSIVES 
 MALES FEMALES MALES FEMALES 
 12 6 17 15 
TOTAL 18 32 
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BODY MASS INDEX 
 
 
 
 
The Body mass index was calculated by the formula  
Weight in kg divided by height in cm squares 
 
 
 
 CASES CONTROLS 
18-22.9 6 10 
22.9-24.9 7 17 
25-30 33 21 
>30 4 2 
TOTAL 50 50 
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Normal   18.5 - 22.9 
Overweight  23.0 - 24.9 
Obese  =>25.0 
 
88 % of cases and 80 % of controls were having a higher than 
normal BMI. The results showed that with increasing obesity the 
prevalence of multiple ischemic events was increasing. An increase in 
BMI with increasing age was observed. The average BMI among cases 
was 27.03. SD was 3.42. Average BMI among controls was 25.4. SD was 
2.97. The p value was 0.0125 which is considered statistically significant. 
There was high prevalence of sedentary life style and faulty eating habits. 
Since both the cases and controls were on atorvastatin therapy they had 
the wide spread belief that they can adopt these faulty habits. Proper 
counselling was given to all the 100 patients included in the study. 
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Waist hip ratio in women 
 
In women Cases Controls 
<o.8  5 7 
>0.8 16 14 
Total 21 21 
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Waist hip ratio in men 
 
In men Cases Controls 
<o.9 7 10 
>o.9 22 19 
Total 29 29 
 
 
 
 
 
 66.6 % of women and 75.8% of men were having a higher than 
normal waist circumference. 
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SERUM LIPID PROFILE 
Total cholesterol HDL Cholesterol and triglycerides were 
measured in overnight fasting of 10 hrs at 7 a.m in the morning using 
Hitachi 704 Analyzer. LDL Cholesterol was calculated by using the 
Freidwald’s formula LDL cholesterol = total chol - [High density 
lipoprotein cholesterol - Triglycerides/5 which is internationally accepted. 
Non HDL cholesterol was calculated by deducting HDL cholesterol from 
total cholesterol. 
 
TRENDS IN TOTAL CHOLESTEROL 
“Total Cholesterol  division 
< 200 good 
200 - 239 slightly High 
>=240 High” 
 
TOTAL CHOL CASES CONTROLS 
<200 29 39 
200-239 19 11 
>240 2 0 
TOTAL 50 50 
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Total cholesterol 
58 % of cases 78 % of controls had their total cholesterol within 
optimal levels. The mean total cholesterol among cases was 197.14 
mg/dl. The mean total cholesterol among controls was 180.34 mg/dl.The 
effect of statins on reducing the total cholesterol was evident. 
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Unpaired t test results 
P value and statistical significance:  
The two-tailed P value equals 0.0050. By conventional criteria, this 
difference is considered to be very statistically significant.  
Confidence interval: 
The mean of Group One minus Group Two equals 16.8000. 
 95% confidence interval of this difference: From 5.2030 to 28.3970  
Intermediate values used in calculations: 
 t = 2.8748:  df = 98.  standard error of difference = 5.844 
Group CASES CONTROLS 
Mean 197.1400 180.3400 
SD 36.0600 20.1800 
SEM 5.0997 2.8539 
N 50 50 
 
 
HDL CHOLESTEROL IN MEN 
HDL cholesterol in men 
MEN HDL CASES CONTROLS 
<= 20 1 0 
21-40 22 13 
41-50 5 11 
51-60 1 4 
>60 0 1 
TOTAL 29 29 
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79.3% of cases and 44.8% of controls had HDL<40 which is 
considered as a significant value for the development of atherosclerosis. 
Women HDL CASES CONTROL 
<20 0 0 
21-40 13 3 
41-50 3 11 
51-60 5 6 
>60 0 1 
TOTAL 21 21 
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HDL CHOLESTEROL IN WOMEN 
 
76.1 % of women cases and 66.6 % of controls had significantly 
low HDL cholesterol. 
The mean HDL cholesterol among (both men and women) cases 
was 37.6 mg/dl. The mean HDL cholesterol among controls was 44.4 
mg/dl. UNPAIRED T TEST RESULTS: 
P value and statistical significance:  
The two-tailed P value is less than 0.0001 
This difference is extremely statistically significant.  Confidence 
interval: The mean of Group One minus Group Two equals -6.6000 95% 
confidence interval of this difference: From -9.7602 to -3.4398  
Intermediate values used in calculations: 
t = 4.1445:df = 98: standard error of difference = 1.592 
 Group  CASES   CONTROLS  
Mean 37.1000 43.7000 
SD 8.1500 7.7700 
SEM 1.1526 1.0988 
N 50   50   
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TRENDS IN TRIGLYCERIDES 
“Triglyceride DIVISION 
< 150  WITHIN normal limits 
150 - 199  Slightly more 
200 - 499  Higher 
>=500 significantly high” 
 
TGL CASES CONTROLS 
<150 5 6 
150-199 24 27 
>199 21 17 
Total 50 50 
Triglycerides 
 
 
Only 10 % of cases and 12 % of controls had optimal triglyceride 
levels. The results indicate that statins did not help much in reducing 
triglycerides in the population studied. 
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The mean triglycerides among cases were 194.4mg/dl. The mean 
triglycerides among controls was 190mg/dl 
Unpaired t test results 
P value and statistical significance: The two-tailed P value equals 
0.5444.This difference is considered to be not statistically significant.  
Confidence interval: The mean of Group One minus Group Two equals 
3.5600. 95% confidence interval of this difference: From -8.0553 to 
15.1753 .Intermediate values used in calculations: 
 t = 0.6082:df = 98: standard error of difference = 5.853 
 Group CASES  CONTROLS 
Mean  193.1600  189.6000 
SD  30.5700  27.9000 
SEM  4.3233  3.9457 
N 50  50  
  
TRENDS IN VLDL 
The average VLDL among cases was 38.8mg/dl. The average 
VLDL among controls was 30mg/dl. Since VLDL was calculated from 
triglycerides test of significance was not applied .  
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TRENDS IN LDL 
LDL Cases Controls 
<70 0 2 
70-99 11 23 
100-129 19 22 
130-159 18 3 
160-189 2 0 
190 and above 0 0 
total 50 50 
 
 
 LDL cholesterol 
 
“LDL <70 Goal LDL for CAD patients 
< 100  Good 
100 - 129  Almost good, borderline good 
130 - 159  Borderline more 
160 - 189  Higher 
>=190 significantly high” 
 73 
LDL CHOLESTEROL 
22% of cases and 46% of controls had their LDL cholesterol within 
optimal results. Only 4 % of controls had reached the target LDL value. 
Since both cases and controls were on regular atorvastatin therapy levels 
the LDL levels of many patients were near optimal levels. The mean LDL 
cholesterol among cases was 121.34 mg/dl. The average LDL Cholesterol 
among controls was 98.72 mg/dl. 
P value and statistical significance: . The two-tailed P value is less 
than 0.0001: This  is considered to be extremely statistically significant.  
Confidence interval: 
 The mean of Group One minus Group Two equals 22.6200 
 95% confidence interval of this difference: From 12.5598 to 
32.6802.  
Intermediate values used in calculations: 
 t = 4.4620:df = 98: standard error of difference = 5.069. 
 Group  CASES    CONTROLS  
Mean 121.3400 98.7200 
SD 27.9300 22.4700 
SEM 3.9499 3.1777 
N 50   50   
   
 
 
 74 
THE NON HDL CHOLESTEROL 
NON HDL Cases  Controls 
<100 0 2 
100-129 10 17 
130-159 14 27 
160-199 24 4 
200 and above 2 0 
total 50 50 
 
 
non HDL cholesterol 
Non HDL cholesterol 
The cut off for non HDL cholesterol is generally thirty mg/dl more than 
LDL cut off values. 38 % of controls had their non-high density 
lipoprotein cholesterol in the optimal range. But only 20 % of cases had 
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their non HDL cholesterol in the optimal range. The mean non HDL 
cholesterol among cases is 160.04 mg/dl. The mean HDL cholesterol 
among controls is 136.64 mg/dl. 
Unpaired t test results 
P value and statistical significance:   The two-tailed P value is less than 
0.0001:  By conventional criteria, this difference is considered to be 
extremely statistically significant.  The mean of cases minus controls 
equals 23.4. 95% confidence interval of this difference: From 13.5500 to 
33.2500. Intermediate values used in calculations: 
 t = 4.7144:df = 98:  standard error of difference = 4.964 d t test results 
Group  cases   controls  
Mean  160.0400  136.6400 
SD  28.3800  20.6500 
SEM  4.0135  2.9204 
N 50  50  
 
This indicates that the difference in non HDL cholesterol contributed 
significantly in the occurrence of a second ischemic event in the form of 
cerebrovascular accident in the study population. Despite statin therapy 
the difference in non HDL cholesterol remains a significant contributing 
factor in the development of cerebrovascular accident. 
  
 
 
 
 
 
 
DISCUSSION 
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DISCUSSION 
Why atorvastatin was chosen? 
It is one of the most commonly prescribed lipid lowering drug in 
our hospital. The most common side effects are hepatotoxicity and 
myopathy. Its beneficial effects include lowering LDL , and triglycerides 
to a certain extent. So the patients on atorvastatin are likely to have less 
LDL cholesterol values than the general population.It does not cause 
significant increase in HDL like that of rosuvastatin. Hence it has little 
effect in altering the non HDL cholesterol value. So the aim was to study  
if non HDL cholesterol has got significant role in assessing CVA risk in a 
population with relatively low LDL levels. It is generally recommended 
in high doses 80 mg/day in the first month of acute coronary syndrome.  
Then gradual tapering is advised and dose is tapered to meet LDL 
goals. In CAD patients the LDL goal is set at 70 mg/dl. It can be 
prescribed at any time of the day preferably at night because the enzyme 
HMG Co A reductase is secreted maximally at night. Other cardiac drugs 
like beta blockers and thiazide diuretics affect lipid profile.  
To have better standards for comparison all patients on atorvastatin 
therapy  who took 10 mg/day were included in the study. The minimum 
intake was set at 1 year. But in our study it was concluded that the 
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majority of patients both cases and controls hadnot attained the goal LDL 
level. Only 2 out of 50 cases and 50 controls had attained the LDL target 
level which is less than 70 mg/dl. However the LDL levels were lesser 
than the levels in general population.  
 
Why non HDL Cholesterol? 
LDL cholesterol is widely recognised as the marker of coronary 
artery disease. Statins have good effect in lowering LDL cholesterol 
values. But still patients develop ischemic events. So the importance of 
looking beyond LDL cholesterol arises. Further non HDL Cholesterol 
is a calculated value using total cholesterol and HDL both of which 
are got from direct measurements whereas LDL cholesterol is a 
predicted value using FRIEDWALDS equation in most of the labs in 
India like our lab. Non HDL cholesterol includes all the atherogenic 
particles in the lipid profile. Hence its considered to have a superior 
predictive value. 
The LDL value reported does not give the actual atherogenic 
LDL values. In our study hence we have focussed on non HDL 
cholesterol which is increasingly recognised as a significant correlate in 
various studies. 
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Why CAD was coupled with CVA? 
The pathogenesis behind coronary artery disease and ischemic 
stroke is the same atherosclerosis. Since it’s easy to recognise a second 
ischemic event at a different site than the same coronary arteries, this dual 
system analysis was conducted. 
Why the duration of occurrence of ischemic events was chosen as 1 to 
5 years? 
I would like to state that this specific duration was chosen to stress 
the high chance of recurrent ischemic events in the study group and for 
chosing a control group who did not develop a cerebral ischemic event 
within the period. 
AGE DISTRIBUTION: 
In our study the mean age of the population was 66.4 years. The 
mean age of first incidence of a coronary event in our population is 53.2 
years and that of CVA is 62.4 years. (meenaksi et al)20. In India we have 
early onset of ischemic events due to genetic factors. 
SEX DISTRIBUTION 
In our study males were more affected than females (29:21). This 
has been reported in various studies. Leading examples include studies by 
Elizabeth et al10. In the majority of studies the ratio is around 2:1. In our 
study the ratio is 29:21. The difference in results could be ignored due to 
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small sample size. This could be because of the greater prevalence of 
metabolic syndrome in females in Trichy district  and also because of a 
slightly elderly population as a study group. Majority of women had 
attained menopause which removes cardio protective activity of 
oestrogen. 
FAMILY HISTORY 
In our study 38 (74%) CAD patients who developed CVA had 
positive family history for ischemic events and 28 (56%) of the controls 
who were CAD patients and did not develop CVA had positive family 
history. This was similar to the study conducted by hoseini et al14. The 
very high prevalence of family history is reported in Indian population so 
also the earlier onset of ischemic event by a decade due to genetic factors. 
SMOKING 
In our study 40% were smokers. Controls were matched for 
smoking. This indicates a high prevalence of ischemic events in people 
who smoke. This has been proved number of times in various studies 
examples include study done by Jeremy et al.15 
ALCOHOLISM 
In our study 40% were alcoholics. Controls were matched for 
alcohol intake. This indicates a high prevalence of ischemic events in 
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people who consume alcohol. This has been proved number of times in 
various studies examples include study done by michael et al.21 
TOTAL CHOLESTEROL 
In our study the average total cholesterol value among cases was 
197.14.  The average of the total cholesterol value among controls was 
found to be 180.34. The p value was found to be p = 0.0050 which was 
found to be statistically significant. The low values were due to the use of 
statins. This is in concordance with the study conducted on total 
cholesterol30 by various studies and Cleveland heart society and ATP 3 
guidelines.31 
LDL CHOLESTEROL 
In our study the average LDL cholesterol value among cases was 
121.34 mg/dl.  The average of the LDL cholesterol value among controls 
was found to be 98.72 mg/dl. Though this was low when compared to 
patients who developed CAD but who were not on STATIN 
therapy(which is 135-140mg/dl) 2,5,20,22 , only 4% of the total 50 % cases 
and 50% controls had attained the target LDL which is set at 70mg/dl. 
The p value was found to be p< 0.0001 which was found to be 
statistically significant. The relatively low values were due to the use of 
statins.  
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TRIGLYCERIDES 
In our study the average triglyceride value among cases was 
193.16.  The average of the triglycerides value among controls was found 
to be 189.6. The p value was found to be 0.544 which was not found to be 
statistically significant. The low values were due to the use of statins. In 
the analysis by miler et al the average triglyceride value was 200.3 on 
patients on statin therapy.22 
HDL CHOLESTEROL 
In our study the average HDL cholesterol value among cases was 
37.1 mg/dl.  The average of the HDL cholesterol value among controls 
was found to be 43.7. The p value was found to be p< 0.0001 which was 
found to be statistically significant. This is in concordance with the study 
conducted on HDL cholesterol by chapman et al where the average HDL 
cholesterol was 36.84 for patients on statin therapy.7 
NON HDL CHOLESTEROL 
In our study the average non HDL cholesterol value among cases 
was 16O.04mg/dl.  The average of the Non HDL cholesterol value among 
controls was found to be 136.64 mg/dl. The p value was found to be 
p< 0.0001 which was found to be statistically significant. Though the 
control group had low values of non HDL cholesterol it was not within 
the target range set by ATP 3 guidelines which is set at 100 mg/dl. This is 
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in concordance with the study conducted by Susan et al where the 
average non HDL cholesterol for patients on statin therapy was 137.2. 
This matches our control population.30 
Pravin et al39 conducted a study to stress the importance of non 
HDL Cholesterol on ischemic stroke patients. The results of the study 
were that the mean non HDL Cholesterol was 198.8 mg/dl. The mean non 
HDL cholesterol of controls was 129.42mg/dl. In this study and other 
similar studies the control population was not CAD patients on statin 
therapy. Hence exact comparison could not be made out. This indicates 
that the difference in non HDL cholesterol contributed significantly in the 
occurrence of a second ischemic event in the form of cerebrovascular 
accident in the study population. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
SUMMARY 
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SUMMARY 
Our study population had significantly low HDL, high Non HDL, 
high LDL values, high total cholesterol values and high BMI compared to 
controls. The Triglyceride matched the control population. The 
importance of non HDL cholesterol is stressed on patients with high 
triglycerides in various literatures. In our population though the 
triglycerides were not significantly elevated the non HDL cholesterol 
values were still significantly high. So it stresses the importance of 
routinely looking beyond LDL cholesterol in all patients. Non HDL 
cholesterol was not superior to LDL cholesterol but was equally 
significant. 
Statins as a class reduce LDL cholesterol. They also reduce total 
cholesterol & triglycerides to a certain extent. But their effect on HDL 
cholesterol is not uniform. Atorvastatin has got no role in reducing non 
HDL cholesterol values. Only newer drugs with high potency including 
rosuvastatin and simvastatin elevate HDL Cholesterol and reduce non 
HDL cholesterol. The importance of non HDL cholesterol is well 
established in patients with elevated triglycerides and diabetes 
population. Our study stresses the importance of routinely focussing on 
non HDL Cholesterol as a parameter as it is more accurate as it’s got by 
deducting total cholesterol from HDL cholesterol both of which are 
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directly measured. Majority of labs report calculated LDL value using 
Friedwalds equation and it does not give us the clinically important 
atherogenic LDL particle level. LDL level is a predicted value. 
In our study patients on atorvastatin therapy were chosen as we 
wanted to stress the importance of non HDL Cholesterol values on 
patients with LDL cholesterol values that were likely to be lower than the 
general population as they were on atorvastatin therapy. However since it 
was a case control study the dose of atorvastatin was not titrated to meet 
the target LDL values and the desired results could not be obtained. But 
still our study clearly establishes the definitive role of non HDL 
cholesterol on par with LDL cholesterol in assessing the risk of ischemic 
stroke.  Drugs that reduce non HDL cholesterol include rosuvastatin, 
simvastatin, niacin and fibrates. However life style modifications are the 
most effective treatment strategy. 
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CONCLUSION 
 Though LDL cholesterol is the most important factor in monitoring 
cerebro vascular risk status and subsequent follow up of risk reduction 
, the case is not always so. 
 In our study LDL cholesterol, HDL cholesterol and non HDL 
cholesterol had equal p values in predicting risk of ischemic 
strokes. 
 In spite of risk reduction with reduction of LDL cholesterol levels in 
certain sub group of patients the risk of atherosclerotic events remains 
high. Other factors like triglycerides, non HDL cholesterol, Apo 
lipoproteins, lipoprotein a and are important. 
 Non HDL cholesterol has a significant contribution in risk assessment 
and goal monitoring in ischemic stroke patients. 
 National cholesterol education program NCEP adult treatment panel 
ATP 3 recommends LDL as the primary target and non HDL as the 
secondary target. Since LDL reported by most of the labs is a 
calculated and predicted value they should be routinely encouraged to 
report the non HDL cholesterol value which is more accurate and 
physicians should routinely target non HDL cholesterol for treatment. 
  
 
 
 
 
 
 
LIMITATIONS 
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LIMITAITONS 
 Dose of atorvastatin was not titrated to the maximum to get LDL 
within target levels as it was a case control study. 
 Low density cholesterol is a calculated value. Exact measurement of 
low density cholesterol particle was not done. 
 Apolipoprotein B was not include in the study 
 The presence of a second ischemic event in the coronary system was 
not included in the study 
 Though the LDL Cholesterol values were low in the study population 
they had not reached the target set by the ATP 3 guidelines 
 Though non HDL cholesterol among controls were low they were not 
in the target set by ATP 3 guidelines. 
 The state of diabetes control was not assertained. But in view that 
diabetes itself contributes to increase risk of stherosclerosis by 
cholesterol pathway the fact may be ignored. 
 Thes state of hypertensive was not assertained as it was a case control 
study. 
 Our study is a study conducted with small sample size. The same 
results may not be obtained in the general population. 
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PROFORMA 
 
Name  :                        Age/Sex :   Occupation : 
Address :      I.P NO : 
Contact No :      D.O.A : 
D.O.D : 
Chief complaints : 
Presenting illness : 
Past History  : 
 
Diagnosed as Coronary artery disease duration in years: 
Diagnosed as diabetes duration in years: 
 
Treatment History   : 
Statin therapy duration  : 
Personal History   : 
Family History   : 
General Examination  : 
Height    : 
Weight    : 
Waist circumference                  :     : 
Body mass Index   : 
Pallor     : 
Icterus    : 
Clubbing    : 
Cyanosis    : 
Lymphadenopathy   : 
Pedal Edema   : 
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Vitals     : 
Temp     : 
Pulse     : 
BP     : 
Respiratory Rate   : 
JVP     : 
Systemic examination  : 
Respiratoy : 
Cardiovascular   : 
Abdomen : 
Central nervous system  : 
 
Investigations   : 
1. Complete blood count 
2. blood sugar 
3. Renal parameters –Blood urea, and  Serum Creatinine 
4. serum Electrolytes. 
5. Fasting Lipid profile 
6. ECG 
7. CXR 
8. CT Brain / MRI Brain 
9. ECHO 
10. Carotid Doppler Study 
 
 
 
 
  
 
 
 
 
 
 
ABBREVIATIONS 
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ABREVIATIONS 
 
ACAT -  acyl co A cholesterol acetyl transferase 
ATPIII - Adult Treatment Panel 
BMI  -  Body Mass Index 
BP   - Blood Pressure 
CAD  - Coronary Artery Disease 
CRP  - C Reactive Protein 
CT   - Computerised tomography 
CVA  - Cerebrovascular accident 
df - discriminative frequency 
DM   - Diabetes Mellitus 
ECG   - Electrocardiogram 
ECHO - Echocardiography 
ESR   - Erythrocyte Sedimentation Rate 
HDL   - High density Lipoprotein 
HT   - Hypertension 
LDL   - Low Density Lipoprotein 
MRFIT -  Multiple Risk Factor Intervention Trial 
MRI   - magnetic resonance imaging 
NPC1L  - Niemen pick like protein  
NSTEMI  - Non ST Elevation Myocardial Infarction 
P value  - Probability value 
PR   - Pulse Rate 
SD - Standard deviation 
SREBP - Selective response element binding protein 
SEM - Standard error of mean 
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STEMI  - ST Elevation Myocardial Infarction 
TC  - Total Count 
TLC   - Therapeutic life style changes 
VLDL  - Very Low density lipoprotein 
WBC  - White blood cell 
WHO  - World Health Organization 
 
MASTER CHART ABBREVIATIONS 
F    - Female 
M   -  Male 
HT    - hypertension 
DM    - diabetes 
S - Smoker 
HDL    - high density lipoprotein  
A    - alcoholic 
Y    - yes 
TC   - total cholesterol 
N    - no 
MCA   -  middle cerebral artery infarct 
PCS   - posterior circulation stroke 
LDL   - low density lipoprotein 
TGL    - triglycerides 
BMI    - body mass index 
ACA    - anterior cerebral artery infarct 
VLDL   - very low density lipoprotein 
 
 
 
  
 
 
 
 
 
 
MASTER CHART 
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cases AGE SEX DM HT S/A CVA TYPE TC HDL NON HDLL TGL BMI
1 52 m y y s/a mca 170 18 152 120 160 23.3
2 45 M y y s/a mca 167 42 125 91 170 18.6
3 60 f y y mca 178 38 140 104 180 19.4
4 65 m y y s/a aca 185 30 155 116 194 23.1
5 64 f n y mca 160 39 121 80 203 19.7
6 58 m y y s/a mca 189 30 159 131 140 23.9
7 68 m y y s/a mca 172 42 130 85 223 23.4
8 75 m n y s/a mca 176 31 145 119 130 22.2
9 64 f n n mca 187 39 148 119 146 26
10 67 m n n s/a mca 211 38 173 135 190 23.5
11 65 m n n s/a mca 190 52 138 96 210 21.4
12 57 m n n s/a mca 156 32 124 95 143 26.4
13 54 m n n mca 180 32 148 120 142 26.7
14 58 f n n pcs 156 32 124 86 190 21.8
15 69 f n n mca 189 45 144 108 180 26.8
16 73 f n n mca 221 42 179 152 134 26.9
17 72 m y y mca 214 43 171 124 234 27
18 65 m y n s/a pcs 160 31 129 84 223 27.1
19 68 m n n mca 215 32 183 140 213 27.2
20 58 m n n mca 153 31 122 84 190 28
21 65 m y y s/a mca 212 29 183 143 199 23.8
22 64 m n y mca 212 28 184 146 189 28.2
23 67 m n n ica 152 35 117 78 195 28.4
24 74 m n n s/a mca 170 28 142 102 198 24.2
25 54 m y y s/a mca 213 35 178 139 194 28.5
26 68 m n n s/a pcs 152 34 118 82 180 28.6
27 76 m n n s/a mca 152 25 127 85 210 28.9
28 65 m y n s/a mca 190 32 158 115 213 29
29 67 m n n mca 231 32 199 153 231 29.4
30 68 m n y s/a mca 212 34 178 134 221 29.8
31 69 f n n a mca 198 35 163 119 221 29.8
32 75 f y y mca 198 35 163 125 190 28
33 76 f n n mca 197 36 161 123 192 29
34 78 f n y a mca 189 38 151 112 195 27.4
35 67 f n y mca 198 39 159 119 198 30.3
36 75 f y n pcs 234 40 194 157 185 34
37 68 f n n mca 221 40 181 144 184 32.3
38 75 m n n s mca 190 21 169 132 185 33.4
39 69 f n n mca 213 37 176 138 192 29
40 74 f y y mca 235 37 198 156 210 29.4
41 74 f n n a mca 221 46 175 129 230 28.4
42 76 f n n mca 223 54 169 121 240 28.9
43 65 f y n mca 224 53 171 125 231 29
44 63 m n y s mca 267 45 222 178 221 29
45 65 m n n s mca 230 34 196 150 231 29.4
46 68 m n n mca 243 36 207 162 224 29.5
47 74 f n n mca 231 50 181 137 221 29.3
48 56 f y n mca 230 52 178 134 221 29.4
49 53 f n n mca 220 54 166 139 134 29.5
50 75 m n n mca 170 42 128 100 212      3025.5
 99 
controlAGE SEX DM HT S/A TC HDL NON HDL LDL TGL BMI
1 52 m y y s/a 201 17 184 152 160 21.6
2 45 m y y s/a 213 50 163 128 174 24.4
3 60 f y y 203 46 157 120 183 21.4
4 65 m y y s/a 202 47 155 117 191 24
5 64 f n y 213 45 168 129 195 24.3
6 58 m y y s/a 198 46 152 124 142 20.6
7 68 m y y s/a 170 36 134 89 223 28
8 75 m n y s/a 220 37 183 157 132 23.1
9 64 f n n 178 44 134 100 168 20.4
10 67 m n n s/a 178 53 125 87 188 23.3
11 65 m n n s/a 190 54 136 107 143 24.5
12 57 m n n s/a 196 52 144 115 143 24.5
13 54 m n n 152 45 107 79 141 19.8
14 58 f n n 189 40 149 110 196 28.9
15 69 f n n 178 50 128 91 184 24.6
16 73 f n n 156 46 110 83 134 28.6
17 72 m y y 200 47 153 125 138 21.8
18 65 m y n s/a 163 38 125 82 214 24.7
19 68 m n n 178 36 142 99 213 28.9
20 58 m n n 176 31 145 107 190 21.4
21 65 m y y s/a 221 42 179 139 199 23.8
22 64 m n y 176 38 138 101 187 23.9
23 67 m n n 175 35 140 101 195 20.4
24 74 m n n s/a 190 45 145 106 197 27
25 54 m y y s/a 152 43 109 72 187 24.3
26 68 m n n s/a 176 41 135 99 180 21.4
27 76 m n n s/a 201 44 157 114 214 23.8
28 65 m y n s/a 153 64 89 46 213 22.1
29 67 m n n 154 32 122 79 213 27.8
30 68 m n y s/a 180 38 142 99 214 27.9
31 69 f n n a 160 35 125 83 212 24.4
32 75 f y y 153 38 115 77 190 24.5
33 76 f n n 205 54 151 113 192 28.9
34 78 f n y a 187 44 143 104 195 24.3
35 67 f n y 152 53 99 59 198 24.5
36 75 f y n 190 46 144 107 185 28
37 68 f n n 200 45 155 118 184 26.7
38 75 m n n s 152 28 124 87 185 26.9
39 69 f n n 153 45 108 70 192 28
40 74 f y y 156 45 111 69 210 27.8
41 74 f n n a 178 46 132 88 221 27
42 76 f n n 160 45 115 73 212 26
43 65 f y n 213 57 156 110 231 27
44 63 m n y s 176 57 119 75 221 28
45 65 m n n s 160 34 126 80 231 30.1
46 68 m n n 170 35 135 90 224 28.7
47 74 f n n 180 53 127 83 221 32
48 56 f y n 186 54 132 88 221 29
49 53 f n n 184 54 130 103 134 29.6
50 75 m n n 170 35 135 101 170 27.4
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CONSENT FORM 
 
 
Name of Researcher: 
 
          
 Please initial box 
 
1. I confirm that I have read and understand the information sheet for the 
above study. I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason. 
 
3.  I understand that any information given by me may be used in future 
reports, articles or presentations by the research team. 
 
4.  I understand that my name will not appear in any reports, articles or 
presentations. 
 
5. I agree to take part in the above study. 
 
 
________________________ ________________
 ________________ 
Name of Participant Date Signature 
 
 
_________________________ ________________
 ________________ 
Researcher Date  Signature 
 
 
 
